BlackRock Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

BlackRock Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$38.1M	Buy	349,828 +24,938	+8%	+$2.78M	0.04%	367
2016 Q3	$39.5M	Sell	324,890 -1,310	-0.4%	-$177K	0.04%	355
2016 Q2	$46.1M	Buy	326,200 +6,012	+2%	+$886K	0.05%	319
2016 Q1	$41.8M	Buy	320,188 +9,093	+3%	+$1.13M	0.04%	351
2015 Q4	$43.7M	Buy	311,095 +169,312	+119%	+$23.5M	0.05%	347
2015 Q3	$18.8M	Sell	141,783 -86,995	-38%	-$15M	0.02%	541
2015 Q2	$40.3M	Buy	+228,778	New	+$41.1M	0.04%	350
2015 Q1	–	Sell	-111,489	Closed	-$18.3M	–	3640
2014 Q4	$18.3M	Sell	111,489 -35,901	-24%	-$5.96M	0.02%	582
2014 Q3	$23.7M	Buy	147,390 +87,937	+148%	+$13.5M	0.02%	524
2014 Q2	$8.74M	Buy	59,453 +11,021	+23%	+$1.53M	0.01%	820
2014 Q1	$6.72M	Buy	48,432 +306	+0.6%	+$46.1K	0.01%	908
2013 Q4	$6.09M	Buy	48,126 +40,757	+553%	+$4.22M	0.01%	945
2013 Q3	$678K	Buy	7,369 +296	+4%	+$23.9K	﹤0.01%	1697
2013 Q2	$486K	Buy	+7,073	New	+$432K	﹤0.01%	1848

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's JAZZ Position: Q4 2016 in Review

BlackRock Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 7.7% in Q4 2016, buying an estimated $2.78M and bringing the position to 349,828 shares worth $38.1M. The position accounts for 0.04% of the portfolio, ranked #367.

BlackRock Advisors first reported a position in JAZZ in Q2 2013 and has held it in 14 quarters since. The position peaked at $46.1M in Q2 2016. 295 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

BlackRock Advisors held 349,828 shares of Jazz Pharmaceuticals worth $38.1M as of Q4 2016.
BlackRock Advisors bought 24,938 Jazz Pharmaceuticals shares in Q4 2016, an estimated $2.78M.
Jazz Pharmaceuticals made up 0.04% of BlackRock Advisors's portfolio in Q4 2016, its #367 holding.
BlackRock Advisors first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
BlackRock Advisors's Jazz Pharmaceuticals position peaked at $46.1M in Q2 2016.
295 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.